Genstar Capital, a private equity firm focused on investments in targeted segments of the financial services, healthcare, industrial technology and software industries, has completed the previously announced acquisition of Advarra, a provider of compliance solutions that are critical to the drug development process, from Linden Capital Partners.
Advarra is a leading provider of institutional review board (IRB), institutional biosafety committee (IBC) and research quality and compliance services, which are mandated by regulatory agencies for all trial protocols, patient forms, site initiations and trial modifications.
The Company serves leading pharmaceutical, biotechnology, medical device and contract research organisations (CROs), as well as academic medical centres, hospital systems, investigative site networks, and therapeutic research consortia, and has relationships with over 3,200 institutional sites. Advarra is headquartered in Columbia, MD and was formed through the merger of Chesapeake IRB and Schulman IRB in 2017; on 28 February, 2019, the Company completed its acquisition of Quorum Review.
